Enterocolitis, Pseudomembranous
"Enterocolitis, Pseudomembranous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.
MeSH Number(s)
C01.252.410.222.310
C06.405.205.596.800
C06.405.469.363.800
Below are MeSH descriptors whose meaning is more general than "Enterocolitis, Pseudomembranous".
Below are MeSH descriptors whose meaning is more specific than "Enterocolitis, Pseudomembranous".
This graph shows the total number of publications written about "Enterocolitis, Pseudomembranous" by people in Harvard Catalyst Profiles by year, and whether "Enterocolitis, Pseudomembranous" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 4 | 1 | 5 |
| 1994 | 12 | 1 | 13 |
| 1995 | 4 | 0 | 4 |
| 1996 | 3 | 1 | 4 |
| 1997 | 4 | 1 | 5 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 3 | 3 | 6 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 6 | 0 | 6 |
| 2008 | 4 | 1 | 5 |
| 2009 | 10 | 0 | 10 |
| 2010 | 3 | 2 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 6 | 0 | 6 |
| 2013 | 8 | 2 | 10 |
| 2014 | 11 | 3 | 14 |
| 2015 | 11 | 3 | 14 |
| 2016 | 3 | 0 | 3 |
| 2017 | 7 | 1 | 8 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 1 | 2 |
| 2021 | 4 | 0 | 4 |
Below are the most recent publications written about "Enterocolitis, Pseudomembranous" by people in Profiles.
-
Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection. Nat Commun. 2021 06 18; 12(1):3748.
-
Proton Pump Inhibitors and Incident Clostridioides difficile Infection: Beyond Controversy, Pragmatic Approaches Are Needed. Clin Infect Dis. 2021 06 15; 72(12):e1090-e1092.
-
Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. Gastroenterology. 2021 05; 160(6):2089-2102.e12.
-
Recurrence of Clostridium Difficile and Cytomegalovirus Infections in Patients with Ulcerative Colitis Who Undergo Ileal Pouch-Anal Anastomosis. Dig Dis Sci. 2021 12; 66(12):4441-4447.
-
Stress ulcer prophylaxis versus placebo-a blinded randomized control trial to evaluate the safety of two strategies in critically ill infants with congenital heart disease (SUPPRESS-CHD). Trials. 2020 Jun 29; 21(1):590.
-
Is it unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent Clostridioides difficile infection? Lancet Gastroenterol Hepatol. 2020 05; 5(5):432-433.
-
Response to: Treatment of (Recurrent) Clostridioides difficile Infections in Children and Adults. J Pediatr Gastroenterol Nutr. 2019 08; 69(2):e58-e59.
-
IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection. Nat Commun. 2019 06 20; 10(1):2712.
-
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019 09; 157(3):682-691.e2.
-
2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019; 14:8.